Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine, Bartosz Chmielowski, Anthony D. Elias, Douglas Adkins, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory Pennock, Meera R. Hameed, Gaurav D. Shah, Amy Qin, Ashwin Shahir, Damien M. Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz

Research output: Contribution to journalArticlepeer-review

495 Scopus citations

Fingerprint

Dive into the research topics of 'Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science